Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE)
Recruiting now · Phase 2
Conditions studied: Sarcoma,Soft Tissue
In brief
Soft tissue sarcomas (STSs) are rare cancers with a 5-year survival rate of 60%, and there is no standard treatment for high-risk extremity and trunk STSs (eSTS). A phase III trial suggests that adding moderate regional hyperthermia (HT) to anthracycline-based chemotherapy, followed by surgery and radiotherapy (RT), can improve 10-year overall survival by 10%. This trial aims to optimize treatment by combining the most effective regimens from chemotherapy, HT, RT, and surgery, and will evaluate the feasibility of this new total neoadjuvant treatment (TNT) approach.
Key facts
- Study ID
- NCT06835049
- Run by
- Swiss Cancer Institute
- People needed
- 24
- Starts
- 2025-10-27
- Expected to finish
- 2031-03-31
- Last updated by the study team
- 2025-12-30
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Kantonsspital Aarau — Aarau, Switzerland (enrolling)
- Universitaetsspital Basel — Basel, Switzerland (enrolling)
- EOC - Istituto Oncologico della Svizzera Italiana — Bellinzona, Switzerland (enrolling)
- Inselspital Bern - Universitätsklinik für Radioonkologie — Bern, Switzerland (enrolling)
- CHUV - Swiss Cancer Center Lausanne — Lausanne, Switzerland (enrolling)
- hoch Health Ostschweiz - Kantonsspital St. Gallen — Sankt Gallen, Switzerland (enrolling)
- Kantonsspital Winterthur — Winterthur, Switzerland (enrolling)
- Universitätsspital Zürich — Zurich, Switzerland (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.